306 related articles for article (PubMed ID: 10215647)
1. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.
Catella-Lawson F; McAdam B; Morrison BW; Kapoor S; Kujubu D; Antes L; Lasseter KC; Quan H; Gertz BJ; FitzGerald GA
J Pharmacol Exp Ther; 1999 May; 289(2):735-41. PubMed ID: 10215647
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
[TBL] [Abstract][Full Text] [Related]
3. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cyclooxygenases reduces complement-induced glomerular epithelial cell injury and proteinuria in passive Heymann nephritis.
Takano T; Cybulsky AV; Cupples WA; Ajikobi DO; Papillon J; Aoudjit L
J Pharmacol Exp Ther; 2003 Apr; 305(1):240-9. PubMed ID: 12649375
[TBL] [Abstract][Full Text] [Related]
5. Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake.
Huledal G; Jonzon B; Malmenäs M; Hedman A; Andersson LI; Odlind B; Brater DC
Clin Pharmacol Ther; 2005 May; 77(5):437-50. PubMed ID: 15900289
[TBL] [Abstract][Full Text] [Related]
6. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects.
Rossat J; Maillard M; Nussberger J; Brunner HR; Burnier M
Clin Pharmacol Ther; 1999 Jul; 66(1):76-84. PubMed ID: 10430112
[TBL] [Abstract][Full Text] [Related]
7. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
[TBL] [Abstract][Full Text] [Related]
8. Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide.
Nüsing RM; Reinalter SC; Peters M; Kömhoff M; Seyberth HW
Clin Pharmacol Ther; 2001 Oct; 70(4):384-90. PubMed ID: 11673754
[TBL] [Abstract][Full Text] [Related]
9. Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men.
Tuleja E; Mejza F; Cmiel A; Szczeklik A
Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1111-5. PubMed ID: 12730088
[TBL] [Abstract][Full Text] [Related]
10. Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis.
Kato S; Ogawa Y; Kanatsu K; Okayama M; Watanabe T; Arakawa T; Takeuchi K
J Pharmacol Exp Ther; 2002 Nov; 303(2):503-9. PubMed ID: 12388629
[TBL] [Abstract][Full Text] [Related]
11. Human pharmacology of naproxen sodium.
Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
[TBL] [Abstract][Full Text] [Related]
12. Acute effects of the anti-inflammatory cyclooxygenase-2 selective inhibitor, flosulide, on renal plasma flow and glomerular filtration rate in rats.
Turull A; Piera C; Queralt J
Inflammation; 2001 Apr; 25(2):119-28. PubMed ID: 11321358
[TBL] [Abstract][Full Text] [Related]
13. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice.
Praticò D; Tillmann C; Zhang ZB; Li H; FitzGerald GA
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3358-63. PubMed ID: 11248083
[TBL] [Abstract][Full Text] [Related]
14. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.
Ehrich EW; Dallob A; De Lepeleire I; Van Hecken A; Riendeau D; Yuan W; Porras A; Wittreich J; Seibold JR; De Schepper P; Mehlisch DR; Gertz BJ
Clin Pharmacol Ther; 1999 Mar; 65(3):336-47. PubMed ID: 10096266
[TBL] [Abstract][Full Text] [Related]
15. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
Schwartz JI; Vandormael K; Malice MP; Kalyani RN; Lasseter KC; Holmes GB; Gertz BJ; Gottesdiener KM; Laurenzi M; Redfern KJ; Brune K
Clin Pharmacol Ther; 2002 Jul; 72(1):50-61. PubMed ID: 12152004
[TBL] [Abstract][Full Text] [Related]
16. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
17. The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial.
Leese PT; Recker DP; Kent JD
J Clin Pharmacol; 2003 May; 43(5):504-13. PubMed ID: 12751271
[TBL] [Abstract][Full Text] [Related]
18. Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine.
Llinás MT; López R; Rodríguez F; Roig F; Salazar FJ
Am J Physiol Renal Physiol; 2001 Nov; 281(5):F975-82. PubMed ID: 11592955
[TBL] [Abstract][Full Text] [Related]
19. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.
Swan SK; Rudy DW; Lasseter KC; Ryan CF; Buechel KL; Lambrecht LJ; Pinto MB; Dilzer SC; Obrda O; Sundblad KJ; Gumbs CP; Ebel DL; Quan H; Larson PJ; Schwartz JI; Musliner TA; Gertz BJ; Brater DC; Yao SL
Ann Intern Med; 2000 Jul; 133(1):1-9. PubMed ID: 10877734
[TBL] [Abstract][Full Text] [Related]
20. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
Ehrich EW; Schnitzer TJ; McIlwain H; Levy R; Wolfe F; Weisman M; Zeng Q; Morrison B; Bolognese J; Seidenberg B; Gertz BJ
J Rheumatol; 1999 Nov; 26(11):2438-47. PubMed ID: 10555907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
